RNA interference (RNAi) as a form of antisense therapy
is also described.
The issuance of this patent expands our intellectual property estate for treating clusterin-expressing cancers using antisense therapy
and provides us with a broad patent that applies well beyond prostate cancer," said Scott Cormack, President and CEO of OncoGenex.
Consisting of 20 papers by an international group of academics and those in industry, the publication covers research on new chemistries, antisense therapy
, the biology and applications of small interfering RNAs, aptamer technology, oligonucleotide-directed alternative splicing, triplex- forming oligonucleotides, immunostimulatory biology and applications, combating HIV infection, and delivery strategies.
The international patents were published under the auspices of the World Intellectual Property Organization according to the Patent Cooperation Treaty (PCT), expanding the CytoGenix patent portfolio of antisense therapy
The pioneering treatment, known as antisense therapy
, was developed at London's Royal Marsden Hospital.
The researchers found that the arteries of rats treated with the antisense therapy
contained no detectable levels of c-myb RNA, while the arteries of rats treated with a control compound had high levels of the substance.
This first-in-human trial of an antisense therapy
for a neurodegenerative disease is the culmination of years of work by scores of people from academia and biotechnology, working in partnership to stop ALS," Dr.
First and foremost, TOPIGEN's proprietary antisense therapy
approach works effectively in the respiratory tract.
The investigators at the Ludwig Institute of the University of California, San Diego and collaborators, funded by The ALS Association, showed that rats and larger lab animals as well respond to the antisense therapy
by producing far less of the targeted protein, copper-zinc superoxide dismutase (SOD1), mutated in some inherited forms of ALS.
Albert Seymour, VP, Discovery Research, Shire, stated: "We are delighted with our partnership with Santaris, whose expertise and capabilities in LNA antisense therapy
complement Shire's drug discovery and development strengths.
Research: innovative areas of research such as antisense therapy
, gene therapy, and cellular therapy in which orphan drugs are playing a key role.
The research papers discuss such topics as hypofolatemia as a risk factor, reduced DNA repair capacity in laryngeal cancer subjects, antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy
, p53-based immunotherapy of cancer, and imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease.